Freedon study: Real‐life outcomes of cenobamate in different lines of treatment
Epilepsia · 2026
DOI: 10.1002/epi.70106 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia, 2026. Verfasst von Vicente Villanueva und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Member of ERN EPICARE, Hospital Universitario y Politécnico La Fe, Valencia, Spain. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Chlorophenols, Tetrazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Angelini Pharma, Sociedad Española de Epilepsia.
Abstract (Originalsprache)
Objectives
Cenobamate is an antiseizure medication (ASM) with proven effectiveness in individuals with highly refractory epilepsy. This study investigated the effectiveness and tolerability of cenobamate in different treatment lines and a less refractory setting.
Methods
This was a multicenter, retrospective, observational study. Adults with focal epilepsy, 2–6 prior ASMs, and ≥12 months between cenobamate initiation and database closure were included. Data from patients' charts were collected and included in the Drug‐Resistant Epilepsy Registry of the Spanish Epilepsy Society using Research Electronic Data Capture. Primary effectiveness endpoints included changes in seizure frequency at 3, 6, and 12 months after cenobamate initiation according to different treatment lines. Primary safety endpoints included the percentage of patients with adverse events (AEs).
Results
In total, 486 patients were included (mean age 42.8 years). The mean number of prior ASMs was 4.4 (2–6); the mean number of concomitant ASMs at cenobamate initiation was 2.5 (1–5). At 12 months, treatment retention was 92% and median dose was 200 mg. One‐year seizure‐freedom rates were 32.5%, 33.3%, 21.4%, 24.2%, and 11.4% in those treated with 2–6 prior ASMs, respectively. The proportions of patients achieving ≥50%, ≥75%, ≥90%, and 100% reductions in seizure frequency at 12 months were significantly higher in patients with 2–3 (earlier treatment lines) vs 4–6 prior ASMs (later treatment lines; p ≤ .004). Improvements in seizure severity were reported in 71.9% of patients during follow‐up (82.5% and 62.1% in those with 2 and 6 prior ASMs, respectively). At 12 months, 56.4% of patients had reported AEs, with somnolence the most frequent, and 4.9% had AEs requiring cenobamate discontinuation. Significance Cenobamate was effective and well tolerated in patients who had tried 2–6 prior ASMs in a real‐world setting. High effectiveness was confirmed at 1 year, with better outcomes in earlier users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Member of ERN EPICARE, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Department of Neurology and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
- Department of Neurology, Hospital Universitario Lucus Augusti, Lugo, Spain.
- Department of Neurology, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
- Department of Neurology, Hospital Universitario Reina Sofía, Córdoba, Spain.
- Department of Neurology, Centro de Neurología Avanzada Sevilla, Sevilla, Spain.
ORCID-Profile: Alejandro Fernández-Cabrera, José C Estevez, Juan Jesús Rodríguez Uranga, Kevin G Hampel, Elena Fonseca, Laura Abraira, Estevo Santamarina, Pablo Cabezudo, Beatriz Cabezas, Marta Marín
Förderung
- Angelini Pharma
- Sociedad Española de Epilepsia
Zitieren
APA
Villanueva, V., Serratosa, J. M., Fernández-Cabrera, A., Toledo, M., González-Giráldez, B., Estevez, J. C., Rodríguez Uranga, J. J., Machio Castelló, M., Castro-Vilanova, M. D., Poza, J. J., Rodríguez-Osorio, X., Hampel, K. G., Fonseca, E., López-González, F. J., Garcés, M., Abraira, L., Ciurans, J., Campos-Fernández, D., Santamarina, E., …, & Pharmacological Therapy Working group of the Spanish Epilepsy Society and Freedon Group (2026). Freedon study: Real‐life outcomes of cenobamate in different lines of treatment. Epilepsia. https://doi.org/10.1002/epi.70106
Vancouver
Villanueva V, Serratosa JM, Fernández-Cabrera A, Toledo M, González-Giráldez B, Estevez JC, et al. Freedon study: Real‐life outcomes of cenobamate in different lines of treatment. Epilepsia. 2026. doi:10.1002/epi.70106
BibTeX
@article{Villanueva2026,
author = {Villanueva, Vicente and Serratosa, José María and Fernández-Cabrera, Alejandro and Toledo, Manuel and González-Giráldez, Beatriz and Estevez, José C and Rodríguez Uranga, Juan Jesús and Machio Castelló, Maria and Castro-Vilanova, Maria Dolores and Poza, Juan José and Rodríguez-Osorio, Xiana and Hampel, Kevin G and Fonseca, Elena and López-González, Francisco Javier and Garcés, Mercedes and Abraira, Laura and Ciurans, Jordi and Campos-Fernández, Daniel and Santamarina, Estevo and Sanchez-Caro, Juan María and Iacampo, Lucas and Renau, Julia and García-Quesada, Miguel Ángel and Anciones, Carla and Chamorro, María Isabel and Maestro, Iratxe and Cabezudo, Pablo and Calle, Raquel and Macarron, Jesús and Cabezas, Beatriz and Carrasco, María and López, María and Marín, Marta and Querol, Rosa and Baena, Belén and García-Morales, Vanessa and López-Maza, Samuel and Juiz, Álvaro and Mercedes-Alvarez, Blanca and Amarante, Carla and Del Villar, Ana and Castillo, Ascensión and Rubio-Roy, Marta and Martinez-Poles, Javier and Gómez-Ibáñez, Asier and Parejo-Carbonell, Beatriz and Martínez Garcia, Anabelén and Carrera, Ignacio and Iriarte, Pablo and Romero-Aguilera, Fátima and Pharmacological Therapy Working group of the Spanish Epilepsy Society and Freedon Group, Pharmacological Therapy Working group of the Spanish Epilepsy Society and Freedon Group},
title = {Freedon study: Real‐life outcomes of cenobamate in different lines of treatment},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70106}
}
EUVIMED